{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:02:56Z","timestamp":1791396176301,"version":"4.3.3"},"reference-count":65,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8,25]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Germ line variants in TERT, SH2B3, TET2, ATM, CHEK2, PINT, and GFI1B are associated with JAK2 V617F clonal hematopoiesis and MPNs. Age-related JAK2 V617F clonal hematopoiesis is found in \u223c2 out of 1000 individuals in the general population.<\/jats:p>","DOI":"10.1182\/blood-2015-06-652941","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T20:52:34Z","timestamp":1467319954000},"page":"1121-1128","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":231,"title":["Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms"],"prefix":"10.1182","volume":"128","author":[{"given":"David A.","family":"Hinds","sequence":"first","affiliation":[{"name":"23andMe, Inc, Mountain View, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly E.","family":"Barnholt","sequence":"additional","affiliation":[{"name":"23andMe, Inc, Mountain View, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Kiefer","sequence":"additional","affiliation":[{"name":"23andMe, Inc, Mountain View, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuong B.","family":"Do","sequence":"additional","affiliation":[{"name":"23andMe, Inc, Mountain View, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Eriksson","sequence":"additional","affiliation":[{"name":"23andMe, Inc, Mountain View, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna L.","family":"Mountain","sequence":"additional","affiliation":[{"name":"23andMe, Inc, Mountain View, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Francke","sequence":"additional","affiliation":[{"name":"23andMe, Inc, Mountain View, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce Y.","family":"Tung","sequence":"additional","affiliation":[{"name":"23andMe, Inc, Mountain View, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huong (Marie)","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University School of Medicine, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gojenola","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University School of Medicine, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Zehnder","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University School of Medicine, Stanford, CA; and"},{"name":"Division of Hematology, Department of Medicine, Stanford University School of Medicine\/Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Stanford University School of Medicine\/Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9464","key":"2019111904262983800_B1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"2019111904262983800_B2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"4","key":"2019111904262983800_B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"2019111904262983800_B4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111904262983800_B5","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"2019111904262983800_B6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111904262983800_B7","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"2019111904262983800_B8","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"24","key":"2019111904262983800_B9","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111904262983800_B10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2019111904262983800_B11","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111904262983800_B12","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111904262983800_B13","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/asheducation-2013.1.538","article-title":"Focus on the epigenome in the myeloproliferative neoplasms.","volume":"2013","author":"Kim","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2019111904262983800_B14","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111904262983800_B15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"2019111904262983800_B16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"2019111904262983800_B17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat Genet"},{"issue":"22","key":"2019111904262983800_B18","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2009-08-236448","article-title":"The JAK2 46\/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.","volume":"115","author":"Jones","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111904262983800_B19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2019111904262983800_B20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2009.226","article-title":"The JAK2 46\/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients.","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"9","key":"2019111904262983800_B21","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2019111904262983800_B22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.","volume":"160","author":"Nielsen","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111904262983800_B23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2006-03-009472","article-title":"JAK2(V617F): Prevalence in a large Chinese hospital population.","volume":"109","author":"Xu","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111904262983800_B24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2141.2006.06483.x","article-title":"JAK2 (V617F) mutation in healthy individuals.","volume":"136","author":"Passamonti","year":"2007","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111904262983800_B25","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.leu.2404292","article-title":"The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors.","volume":"20","author":"Sidon","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"2019111904262983800_B26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"issue":"26","key":"2019111904262983800_B27","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes.","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111904262983800_B28","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111904262983800_B29","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies.","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"7319","key":"2019111904262983800_B30","first-page":"1061","article-title":"A map of human genome variation from population-scale sequencing [published correction appears in Nature. 2011;473(7348):544].","volume":"467","author":"Abecasis","year":"2010","journal-title":"Nature"},{"issue":"5","key":"2019111904262983800_B31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/521987","article-title":"Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering.","volume":"81","author":"Browning","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"8","key":"2019111904262983800_B32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ng.2354","article-title":"Fast and accurate genotype imputation in genome-wide association studies through pre-phasing.","volume":"44","author":"Howie","year":"2012","journal-title":"Nat Genet"},{"issue":"4","key":"2019111904262983800_B33","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/genetics\/164.4.1567","article-title":"Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies.","volume":"164","author":"Falush","year":"2003","journal-title":"Genetics"},{"issue":"4","key":"2019111904262983800_B34","doi-asserted-by":"crossref","first-page":"e34267","DOI":"10.1371\/journal.pone.0034267","article-title":"Cryptic distant relatives are common in both isolated and cosmopolitan genetic samples.","volume":"7","author":"Henn","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"2019111904262983800_B35","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/ng1847","article-title":"Principal components analysis corrects for stratification in genome-wide association studies.","volume":"38","author":"Price","year":"2006","journal-title":"Nat Genet"},{"issue":"4","key":"2019111904262983800_B36","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.0006-341X.1999.00997.x","article-title":"Genomic control for association studies.","volume":"55","author":"Devlin","year":"1999","journal-title":"Biometrics"},{"issue":"1","key":"2019111904262983800_B37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"2019111904262983800_B38","doi-asserted-by":"crossref","first-page":"242151","DOI":"10.1155\/2009\/242151","article-title":"Chromosome 5p region SNPs are associated with risk of NSCLC among women.","volume":"2009","author":"Van Dyke","year":"2009","journal-title":"J Cancer Epidemiol"},{"issue":"8","key":"2019111904262983800_B39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/ng.2353","article-title":"A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population.","volume":"44","author":"Shiraishi","year":"2012","journal-title":"Nat Genet"},{"issue":"4","key":"2019111904262983800_B40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2566","article-title":"Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.","volume":"45","author":"Bojesen","year":"2013","journal-title":"Nat Genet"},{"issue":"11","key":"2019111904262983800_B41","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jnci\/djs222","article-title":"Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis.","volume":"104","author":"Mocellin","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"2019111904262983800_B42","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.707.707","article-title":"A germline variant in the TERT gene is a novel predisposition allele associated with myeloproliferative neoplasms [abstract].","volume":"120","author":"Hinds","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111904262983800_B43","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/leu.2014.48","article-title":"The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms.","volume":"28","author":"Oddsson","year":"2014","journal-title":"Leukemia"},{"key":"2019111904262983800_B44","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat Commun"},{"issue":"5","key":"2019111904262983800_B45","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2013-10-532622","article-title":"Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms.","volume":"123","author":"Lesteven","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111904262983800_B46","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20040762","article-title":"Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.","volume":"200","author":"Tong","year":"2004","journal-title":"J Exp Med"},{"issue":"8","key":"2019111904262983800_B47","first-page":"2832","article-title":"Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.","volume":"118","author":"Bersenev","year":"2008","journal-title":"J Clin Invest"},{"issue":"12","key":"2019111904262983800_B48","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1084\/jem.20011883","article-title":"Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice.","volume":"195","author":"Velazquez","year":"2002","journal-title":"J Exp Med"},{"issue":"22","key":"2019111904262983800_B49","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers.","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111904262983800_B50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111904262983800_B51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms.","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111904262983800_B52","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Genet"},{"issue":"5449","key":"2019111904262983800_B53","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1126\/science.286.5449.2528","article-title":"Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.","volume":"286","author":"Bell","year":"1999","journal-title":"Science"},{"issue":"1","key":"2019111904262983800_B54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","article-title":"Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.","volume":"31","author":"Meijers-Heijboer","year":"2002","journal-title":"Nat Genet"},{"issue":"21","key":"2019111904262983800_B55","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1093\/hmg\/ddl401","article-title":"Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives.","volume":"15","author":"Webb","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"9","key":"2019111904262983800_B56","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1158\/1055-9965.EPI-10-0374","article-title":"Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.","volume":"19","author":"Fletcher","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"2019111904262983800_B57","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2005-12-5022","article-title":"Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia.","volume":"108","author":"Rudd","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111904262983800_B58","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1373\/clinchem.2004.038331","article-title":"Locked nucleic acid-enhanced detection of 1100delC*CHEK2 germ-line mutation in Spanish patients with hematologic malignancies.","volume":"50","author":"Collado","year":"2004","journal-title":"Clin Chem"},{"issue":"3","key":"2019111904262983800_B59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3324\/haematol.2011.049494","article-title":"A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations.","volume":"97","author":"Janiszewska","year":"2012","journal-title":"Haematologica"},{"issue":"9","key":"2019111904262983800_B60","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/gb-2013-14-9-132","article-title":"PINTing for p53.","volume":"14","author":"Shiekhattar","year":"2013","journal-title":"Genome Biol"},{"issue":"14","key":"2019111904262983800_B61","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood-2009-09-241752","article-title":"Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage.","volume":"115","author":"Randrianarison-Huetz","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111904262983800_B62","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa1308130","article-title":"A dominant-negative GFI1B mutation in the gray platelet syndrome.","volume":"370","author":"Monteferrario","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111904262983800_B63","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/ng.2270","article-title":"Detectable clonal mosaicism and its relationship to aging and cancer.","volume":"44","author":"Jacobs","year":"2012","journal-title":"Nat Genet"},{"issue":"6","key":"2019111904262983800_B64","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/ng.2271","article-title":"Detectable clonal mosaicism from birth to old age and its relationship to cancer.","volume":"44","author":"Laurie","year":"2012","journal-title":"Nat Genet"},{"issue":"3","key":"2019111904262983800_B65","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States.","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/8\/1121\/1465033\/1121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/8\/1121\/1465033\/1121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T09:52:24Z","timestamp":1656755544000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/8\/1121\/35712\/Germ-line-variants-predispose-to-both-JAK2-V617F"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-06-652941","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726475066.793523986","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}